Explore the words cloud of the NO-META project. It provides you a very rough idea of what is the project "NO-META" about.
The following table provides information about the project.
CYTOFIND DIAGNOSTICS BV
|Coordinator Country||Netherlands [NL]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2016-08-01 to 2016-12-31|
Take a look of project's partnership.
|1||CYTOFIND DIAGNOSTICS BV||NL (BEEK UBBERGEN)||coordinator||50˙000.00|
Circulating Tumour Cells (CTCs) are strong indicators of the aggressiveness of metastatic cancer and there is strong evidence that CTCs are a reliable prognostic factor in patients with early-stage and metastatic breast cancer. Despite significant efforts, the detection and identification of CTCs in peripheral blood has proven difficult. The key technical challenge is posed by the rarity of tumour cells in blood, with estimates of just one CTC per ~1-10 million white blood cells per millilitre of blood. Up until now, there has been only one FDA-approved CTC enumeration system, CellSearch®, yet this state-of-the-art method suffers from severe limitations. There is an urgent need for new, alternative methods of CTCs enumeration and further characterization to fully realize the potential clinical benefits of CTC analysis. Lowering cost and speed of analysis coupled with ability to isolate CTC for further analysis would have a tremendous effect on diagnostics and treatment of cancer patients. It would provide novel means for early screening of individuals in a certain risk groups, elucidating most promising therapy options and following a chosen treatment and providing a cost-effective way to monitor patients in risk of relapse. Cytofind Diagnostics has developed a radically new method to count and isolate CTCs based on single cell determination of the anomalous metabolic properties of tumour cells (the so-called Warburg effect). Here, we wish to carefully analyze the potential impact of our technology on different parts of the oncology care cycle and establish which market is most suitable for the first introduction of our disruptive technology.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NO-META" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "NO-META" are provided by the European Opendata Portal: CORDIS opendata.
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
Global Alliance for Chronic Diseases SecretariatRead More
CeLac and European consortium for a personalized medicine approach to Gastric CancerRead More